We analyze in the current study the impact of heptaminol hydrochloride (Heptamyl) administration in patients with septic shock requiring adrenergic support on the duration of vasopressor infusion and on catecholamine delay weaning. In this prospective study were included 49 nonconsecutive patients with septic shock requiring vasopressor infusion and with stable hemodynamic parameters during more than 24 hours. All these patients were included in a random way to receive or not heptaminol hydrochloride. The primary end point was the effect of heptaminol hydrochloride administration on duration of weaning, defined as cessation of vasopressor support. There were 32 males (65%) and 17 females (35%). The mean age (6 standard deviation) was 53.9 6 22.2 years. Norepinephrine was the most commonly used vasopressor agent (73.4 %). The comparison between two groups (with and without heptaminol hydrochloride) showed that two groups had the same epidemiologic, clinical, and biologic findings on intensive care unit admission. In our study, we found that the introduction of Heptamyl was associated with a quick decrease of dose of dopamine and norepinephrine in comparison with the Heptamyl-free group. By comparing the two groups, we found that the delay of catecholamine weaning was significantly faster for the dopamine (P = 0.008) and noradrenalin (P = 0.001) in the Heptamyl group. Finally, the intensive care unit mortality rate and the hospital mortality rate were significantly lower in the Heptamyl group. Our study shows a reduction in norepinephrine and dopamine weaning duration in septic patients enrolled in the heptaminol hydrochloride group.
INTRODUCTION
Sepsis, inflammatory response to infection, contributes directly or indirectly to mortality in the majority of critically ill patients. An elevated cardiac index and a decreased systemic vascular resistance leading to hypotension and hypoperfusion of vital organs characterize the early stage of septic shock. The hypotensive state is often not amenable to fluid resuscitation alone and requires institution of vasoactive agents to counter the profound fall in systemic vascular resistance, which is an integral feature of septic shock. 1, 2 The optimal adrenergic support in shock is controversial. Dopamine and norepinephrine are the most commonly used agents to restore tissue perfusion pressure in these conditions. 1 Both have their advantages and potential disadvantages such as increased heart rate and tachyarrhythmias, pituitary dysfunction, hyperglycemia, hypokalemia, and excessive vasoconstriction, particularly in those with critical illness. 1 For these reasons, catecholamine infusion should be stopped as soon as possible. As soon as hemodynamic variables are stable, vasopressor and inotropic support should be gradually weaned to decrease duration of shock and avoid adrenoreceptor downregulation and catecholamine refractoriness. 3 However, there is little published evidence on how to wean support and the weaning rate is usually chosen empirically. 4 Heptaminol hydrochloride is widely used for the treatment of orthostatic hypotension. It has an inotropic action. Moreover, heptaminol hydrochloride prevented orthostatic hypotension and increased the noradrenaline plasma concentration by a competitive inhibition of noradrenaline uptake. 5 This inhibition may partially explain antihypotensive effect. 5 For these reasons, we have postulated that heptaminol hydrochloride administration in patients with vasoplegic shock requiring adrenergic support can be used as an adjunctive therapy to decrease duration of vasopressor infusion leading to catecholamine weaning in vasoplegic shock.
PATIENTS AND METHODS
This study was approved by an Internal Review Boards and consent was obtained by the patient surrogates in all cases.
It is a prospective study conducted between January 1, 2009 and March 2009 in the intensive care unit (ICU) of Habib Bourguiba University Hospital (Sfax, Tunisia). Our department is a 22-bed medical surgical ICU in a teaching hospital of 510 beds located in south Tunisia. Included patients were older than age 18 years having confirmed septic shock admitted to our ICU. Reasons for exclusion were pregnancy, history of heart failure, evidence of obstructive cardiomyopathy, acute myocardial ischemia or pulmonary embolism, advancedstage cancer, stroke, comatose state after cardiac arrest, and malignant hemopathy.
Infection was defined as the isolation of a pathogenic microorganism and/or the presence of clinical infection needing antibiotic administration, and ICUacquired infection was defined as infection occurring 48 hours or more after ICU admission. 1 Sepsis is defined as infection plus systemic manifestations of infection. 2 Severe sepsis is defined as sepsis plus sepsisinduced organ dysfunction or tissue hypoperfusion. 2 Sepsis-induced hypotension is defined as a systolic blood pressure (SBP) of less than 90 mm Hg or mean arterial pressure less than 70 mm Hg or a SBP decrease greater than 40 mm Hg or less than 2 standard deviations below normal for age in the absence of other causes of hypotension. 2 Septic shock is defined as sepsis-induced hypotension persisting despite adequate fluid resuscitation requiring vasopressor infusion and as the association of shock and infection. 2 Sepsisinduced tissue hypoperfusion is defined as either septic shock and elevated lactate or oliguria. 2 Included in our study were 49 nonconsecutive patients who developed septic shock. Infection was confirmed in all cases. All patients received volume expansion that was started before vasopressor infusion. Fluid resuscitation consisted of colloid and crystalloid solutions, and blood hematocrit was maintained greater than 30% with blood transfusion.
When patients fulfilled these inclusion criteria (confirmed septic shock), a continuous infusion of either dopamine or norepinephrine was started through a separate central venous line and an automatic pump. Dopamine was used as an infusion solution containing 5 mg/mI and 1 mg/mL norepinephrine. For each patient, drug dilutions were prepared. Dopamine was started at a dose of 5 mg/kg/min; this dose can be gradually increased up to a maximum dose of 25 mg/kg/min. The other solution contained norepinephrine diluted so that an infusion of 1 mL/hour allowed us to deliver to the patient 1 mg/hour. Then catecholamine doses were progressively increased after 10-to 20-minute intervals when hemodynamic abnormalities were not corrected. In our institution, epinephrine was not systematically used in septic shock. It was used only when other vasopressor failed to restore stable hemodynamic status. Finally, dobutamine is not routinely used in septic shock because it can lower systemic vascular resistance; this leads to a risk of hypotension and it was used only when cardiac and associated dysfunction is suspected.
In our institution, the optimal dose of catecholamine is the mean dose leading to a good perfusion pressure with a mean arterial pressure of 65 to 75 mm Hg and absence of signs of tissue hypoperfusion and hypoxia, including an altered level of consciousness, oliguria, or cool, clammy extremities.
All patients with stable hemodynamic status (with stable mean arterial pressure, absence of tissue hypoperfusion, and without need to increase the dose of vasopressor during more than 24 hours) were included in our study. All these patients were included in a random way to receive or not heptaminol hydrochloride (Heptamyl, Sanofi-Synthélabo, Paris, France). Many patients were excluded either because they did not fulfill inclusion criteria or because they were not stable enough to start the catecholamine weaning process. For these reasons, patients were not consecutively included. Heptamyl was administered enterally to patients with adequate gastrointestinal motility and adsorption. So two groups of patients were analyzed; the first group included all patients receiving heptaminol hydrochloride and the second group included all patients free of heptaminol hydrochloride. In our study, heptaminol hydrochloride was administrated in its solution form (drops with 30.5%: 20 drops contain 254 mg). The mean dose used was the mean dose used was 30 to 50 drops three times/day (381-635 mg three times/ day) or 12 mg/kg orally daily, which is the usual dose used for patients with orthostatic hypotension. This dose is usually rapidly and entirely absorbed. 6 A daily evaluation of doses of vasopressor, hemodynamic parameters, including systolic arterial blood pressure, diastolic arterial blood pressure, heart rate, signs of tissue hypoperfusion, and urinary output, was performed. Moreover, arterial blood gases and acid-base status (pH and HCO 3 ) were also daily analyzed for each patient. Moreover, on inclusion, patients were followed throughout their ICU stay or until death. The following were recorded daily while the patients were receiving norepinephrine or dopamine in the ICU: dose of vasopressor, vital signs, standard laboratory variables, results for cultures of specimens from new infection sites, and interventions. The primary end point was the effect of heptaminol hydrochloride administration on duration of weaning, defined as cessation of vasopressor support. The secondary end points were ICU mortality, hospital mortality, and length of stay in the ICU.
For all included patients, a data entry form was designed to collect demographic, clinical, and radiologic data on admission and during the ICU stay. Medical files were prospectively reviewed and the following data collected on hospital admission, ICU admission, and during ICU stay: age, sex, heart rate, respiratory rate before mechanical ventilation, blood pressure, use of inotropic drugs, the presence of shock, fluid intake volume, and urinary output. The systemic inflammatory response syndrome 7 was also researched on admission and during the ICU stay. Biochemical parameters measured on admission and during the ICU stay are arterial blood gases and acidbase status (pH and HCO 3 ), leukocyte counts, hemoglobin concentration, and so on. Moreover, for each patient, the severity of illness was estimated with the Simplified Acute Physiology score calculated within 24 hours of admission 8 and according to the Acute Physiology and Chronic Health Evaluation categorization at admission. 9 Clinical and laboratory data for Simplified Acute Physiology 8 were reported as the worst value within 24 hours after admission. Microbiologic and clinical infections were reported daily as well as the antibiotics administered. During the ICU stay, all complications were recorded: nosocomial infections, 10 pneumonia, thrombocytopenia, gastrointestinal bleeding, cerebral hemorrhage, and hematomas. For each patient, the number of organ failures 10 was calculated.
Statistical analysis
Categorical data are expressed in proportion and subgroups (with and without heptaminol hydrochloride) are analyzed by the chi-square test. Continuous variables are expressed as means (6 standard deviation) and subgroups evaluated by Student t test.
RESULTS
During the study period, 360 patients were admitted in our ICU. Forty-nine patients developed septic shock with all inclusion criteria and were all included in this study. In our study, the most common causes of ICU admission were: polytrauma in 17 (34%) patients, respiratory distress in three (6.2%), shock in five (10.2%), and postsurgical admission in 19 (38.7%).
There were 32 males (65%) and 17 females (35%). The mean age (6 standard deviation) was 53.9 6 22.2 years with a range of 18 to 91 years. Twenty-two patients (45%) were older than 60 years.
The clinical presentations of the study group on admission are shown in Table 1 . In our study, 32 Norepinephrine was the most commonly used vasopressor agent (73.4%), used as a single agent in 34.7% of patients with shock. Dopamine was used in 13 (26.5%) patients as a single agent in seven (14.3%) patients and combined with other vasopressor (most commonly with norepinephrine) in six (12.2%). Epinephrine was used less commonly (26.5%) and rarely as a single agent (6%). Dobutamine was combined with other catecholamines in 34% of patients, mostly with norepinephrine (18.3%). All four catecholamines were administered simultaneously in 2.2% of patients ( Table 2) .
The comparison between the two groups (with and without heptaminol hydrochloride) showed that they had the same epidemiologic, clinical, and biologic findings on ICU admission (Tables 3 and 4) . Moreover, the comparison between two groups showed that there is no significant difference either in the choice of molecule of catecholamine used or in the dose used (Table 5 ). In fact, as shown in table 5, our study includes two groups of patients with the same dose of vasopressor on inclusion except for epinephrine. Furthermore, as shown in Table 6 , the comparison between two groups showed that there is no significant difference in hemodynamic parameters the day of inclusion.
In our study, we found that the introduction of Heptamyl was associated with a quick decrease of dose of dopamine and norepinephrine in comparison with the Heptamyl-free group (Table 7 ; Figs. 1 and 2) . As shown in Figures 3 and 4 , despite the decrease of catecholamine dose in the Heptamyl group, all hemodynamic parameters of this group improved.
By comparing the two groups, we found that mean time of catecholamine withdrawal was significantly shorter for the dopamine and noradrenalin in the Heptamyl group. Indeed, the mean delay of dopamine weaning was of 36 6 16 hours versus 141 6 67 hours (P = 0.008) and the mean time of norepinephrine weaning was 35 6 30 hours versus 89 6 44 hours (P = 0.001), respectively (Table 8 ; Fig. 5 ). Moreover, renal function was not affected by the use of Heptaminol in the patients studied. Finally, the ICU mortality rate and the hospital mortality rate were significantly lower in the Heptamyl group (Table 8 ).
DISCUSSION
The main findings of this study were that treatment with heptaminol hydrochloride decreased the duration of shock and duration of vasopressor infusion leading to catecholamine weaning in vasoplegic shock.
Septic shock is a serious medical condition caused by decreased tissue perfusion and oxygen delivery as a result of infection and sepsis. It can cause multiple organ dysfunction syndrome (formerly known as multiple organ failure) and death. [1] [2] [3] [4] Despite advances in critical care, the death rate from severe sepsis remains approximately 30% to 50%. 4 It is generally agreed that fluid resuscitation and vasopressors should be initiated promptly to treat shock and organ failure and rapidly restore the mean arterial pressure to 60 to 80 mm Hg. 4 The vasopressor in most common use is norepinephrine (noradrenaline) but, because of its weak inotropic effect and concerns about regional blood flow, dobutamine is often administered concomitantly. As soon as hemodynamic variables are stable, vasopressor and inotropic support are gradually weaned to decrease duration of shock and avoid adrenoreceptor downregulation and catecholamine refractoriness. 4 However, there is little published evidence on how to wean vasopressor support. The weaning rate is usually chosen empirically.
Until now, the effects of corticosteroids on circulatory response in critically ill patients are known, although not fully understood. By elevating cortisol levels, the body attempts to adapt to stress associated with critical illness. 11 Cortisol apparently contributes to maintain cardiac contractility, vascular tone, and blood pressure by mediating and enhancing the action of angiotensin II, epinephrine, and norepinephrine. 12 The study by Annane et al 13 showed a reduced time of shock reversal and a lower mortality in patients with septic shock with relative adrenal insufficiency when they were treated with low-dose steroid therapy (LDST). However, this study has been criticized; because the biochemical diagnosis of relative adrenal insufficiency is not clear and most patients previously received etomidate, a well-known agent that interferes in steroidogenesis, 14 and moreover, patients with preserved adrenal response in the study who were treated with LDST showed a trend to increased mortality and no differences in time of shock reversal. 13 The Surviving Sepsis Campaign guidelines, 15 following several cited studies, support LDST use in vasopressor-dependent patients with septic shock. However, its widespread use in this setting has been recently criticized. 16, 17 In our study, all included patients were treated with LDST. Excluded were all patients with instable hemodynamic status requiring to increase the dose of vasopressor despite fluid resuscitation and use of vasopressor and steroids. For these reasons, catecholamine weaning is not possible (in patients with unstable hemodynamic status) and our series includes nonconsecutive patients. Moreover, we found that treatment with heptaminol hydrochloride decreased duration of shock and duration of vasopressor infusion leading to quick catecholamine weaning in septic shock.
Moreover, we found that despite the decrease of catecholamine dose in the Heptamyl group, all hemodynamic parameters (SBP, diastolic blood pressure, pH, HCO 3 ) in this group were improved. In addition, the ICU mortality rate and the hospital mortality rate were significantly lower in the Heptamyl group.
In fact, heptaminol is a molecule with experimental cardiovascular analeptic properties. 5 Heptaminol hydrochloride, which is widely used for the treatment for orthostatic hypotension, has probably an inotropic action. 5 Moreover, heptaminol hydrochloride prevented orthostatic hypotension and increased the noradrenaline plasma concentration by a competitive inhibitor of noradrenaline uptake. 5 In a double-blind versus placebo trial, 18 the potency of the injectable form of a 626-mg dose of heptaminol chlorhydrate on spontaneous or induced orthostatic hypotension was assessed. Nineteen patients were included in the study: seven displayed spontaneous orthostatic hypotension, and in the other 12, orthostatic hypotension was induced by bromocriptine as monitored 103 min/after an oral intake of 6.6 mg on average. Potency tilt trials, performed 15, 30, and 45 minutes after parenteral administration of heptaminol, revealed a significant and expressive potency of the molecule on the SBP after 15 minutes (P , 0.05). In this study, clinical and biologic tolerance was excellent. Low plasma renin activity and the absence of response to orthostatism indicated, in this population of parkinsonian extrapyramidal syndromes, a loss in positive tonus likely to be of sympathetic origin. The authors conclude that the antihypotensive action of heptaminol seems not to be related to any renal or even sympathetic interaction.
However, in an experimental study, it was clearly established that heptaminol was also found to be a competitive inhibitor of noradrenaline uptake. 19 Our results agree with this last hypothesis; in fact, the introduction of heptaminol in our study was associated with a quick decrease of dose of dopamine and norepinephrine in comparison with the Heptamyl-free group.
Despite the decrease of catecholamine dose in the Heptamyl group, all hemodynamic parameters of this group were improved. Moreover, by comparing the two groups, we found that the delay of catecholamine weaning was significantly shorter for the dopamine and noradrenalin in the Heptamyl group. Finally, the ICU mortality rate and the hospital mortality rate were significantly lower in the Heptamyl group.
In conclusion, heptaminol hydrochloride administration in patient with vasoplegic shock requiring adrenergic support can be used as an adjunctive tool to decrease duration of vasopressor infusion leading to catecholamine weaning in vasoplegic shock. This findings can be probably explained by the fact that heptaminol was also found to be a competitive inhibitor of noradrenaline uptake. 19 
